Skip to content

Pipeline
- Overview
- Clinical Trials
Technology
- The DRP^® Method
- Scientific Publications
About Us
Investors
Newsroom
- Top News
- Media Contact
Contact
- General Inquires
Careers
- Join Allarity
- Submit Resume

Menu

Pipeline
- Overview
- Clinical Trials
Technology
- The DRP^® Method
- Scientific Publications
About Us
Investors
Newsroom
- Top News
- Media Contact
Contact
- General Inquires
Careers
- Join Allarity
- Submit Resume

Search

Close

Pipeline: Clinical Trials

Clinical trials involving Allarity assets include:

Dovitinib

Stenoparib (2X-121)

Stenoparib (2X-121) (Phase 2)

Under previous name (E7449)

Ixempra^®

Irofulven

Irofulven (Phase 2)

2X-111

Under previous name (2B3-101)

LiPlaCis^®

LiPlaCis (Phase 2)

Pipeline
Overview
– Dovitinib
– Stenoparib
– Ixempra^®
– Additional Programs
Clinical Trials

Technology The DRP^® Platform Scientific Publications

About Us
Overview
Leadership
Board of Directors
SAB
Partnering

Investors
Overview
Press Releases
Events & Presentations
Financials
Stock Information
Analyst Coverage
Corporate Governance
Contact

Newsroom
Top News
Media Contact

Contact
General Inquires

Careers
Join Allarity
– Submit Resume

Copyright © 2020 Allarity Therapeutics A/S. All Rights Reserved.

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

Social Media Policy

United States:
210 Broadway # 201
Cambridge, MA 02139
USA

Denmark:
Venlighedsvej 1
DK-2970 Hørsholm
CVR: 2810 6351
Tel. +45 53 61 15 70

Oncology Venture is now

Allarity Therapeutics

At Allarity Therapeutics, we are defining a bright future for patients in a new paradigm of precision cancer treatments. Our mission is to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.